Recent findings from the ZENITH-CKD Phase IIb trial, conducted by AstraZeneca, have demonstrated a significant decrease in albuminuria among CKD patients treated with a combination of Zibotentan and Dapagliflozin. The trial has brought to light a notable decrease in the urinary albumin-to-creatinine ratio (UACR) in participants, offering a new avenue for CKD treatment. Significant UACR […]
Swiss pharmaceutical giant Novartis has wrapped up the previously announced $3.5 billion acquisition of Seattle-based biopharmaceutical firm Chinook Therapeutics, Inc. This deal propels Novartis deeper into the realm of kidney disease treatments, capitalizing on Chinook Therapeutics’ cutting-edge precision medicines. Chinook Therapeutics’ promising pipeline, boasting two advanced assets, atrasentan and zigakibart (BION-1301), specifically targets Immunoglobulin A […]
Apellis Pharmaceuticals has reported positive results for pegcetacoplan from the phase 2 DISCOVERY clinical trial in patients with C3 glomerulopathy (C3G), a type of kidney disease. According to the US biopharma company, the 48-week results demonstrated that patients subjected to pegcetacoplan had sustained improvements across key clinical measures. These include a greater than 65% mean […]
Swedish pharmaceutical company Calliditas Therapeutics has initiated the Phase 3 NEFIGARD trial to evaluate its lead drug candidate, Nefecon, for treating IgA nephropathy (IgAN), commonly known as Berger’s disease. The NEFIGARD trial marks a significant step for Calliditas Therapeutics as it begins enrolling patients for a late-stage study designed to assess the effectiveness of Nefecon […]